“Internal neurostimulation involves a surgical implantation of electrodes at specific areas, either in the dura mater or deep inside the brain. Medical practitioners measure the invasiveness of any surgical procedure or therapeutic device, based on incision size, collateral tissue damage, and recovery period. Thus, minimally invasive technologies are surgical techniques that reduce the physical impact of a medical procedure. The use of internal neurostimulation (minimally invasive) devices reduces the length of hospital stay, post-surgical complications, and improves the quality of life. The long-term cost savings associated with the use of minimally invasive neurostimulation devices has contributed to the significant growth of the internal neurostimulation market.
In addition to this, increasing neurostimulation research activities to treat diabetes, widespread awareness associated with the benefits of neurostimulation methods, and growing prevalence of neurological disorders have equally contributed to the overall growth of the global internal neurostimulation market.
The global internal neurostimulation market was valued at $4,850.1 million in 2014, and is expected to reach $8,585.1 million by 2019, at a CAGR of 12.1% from 2014 to 2019. The North American internal neurostimulation market was valued at $2,513.0 million in 2014, and is expected to reach $4,186.1 million by 2019, at a CAGR of 10.7% during the forecast period.
“
